Secretome Therapeutics Highlights Patient-Centric Approach at Advanced Therapies Week

According to a recent LinkedIn post from Secretome Therapeutics, the company participated in Advanced Therapies Week 2026 in San Diego, where its VP of Clinical Development joined a fireside chat with Parent Project Muscular Dystrophy. The session focused on the role of patient advocacy in shaping early clinical development, emphasizing that patient perspectives can be foundational to clinical strategy rather than peripheral.

The post suggests that Secretome Therapeutics is positioning itself as closely aligned with patient advocacy groups in areas such as trial design and endpoint selection. For investors, this approach may indicate a strategic focus on patient-centric development in advanced therapies, which could support better trial recruitment, regulatory receptivity, and long‑term differentiation in the competitive cell and gene therapy landscape.